Relevium Enters Into Manufacturing Agreement With Bio V Pharma and Registers 400 NPN Numbers With Health Canada
10 October 2019 - 6:05AM
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to
announce today that it has registered four hundred (400) Natural
Product Numbers (NPNs) with Health Canada through its main brand,
Bioganix®, and entered into a manufacturing agreement with Bio V
Pharma Inc. (“Bio V Pharma”), to manufacture, label and package
Bioganix® products.
Bio V Pharma is a Quebec-based,
full-service manufacturer of pharmaceutical and nutraceutical
products including vitamins, botanical products, food and
veterinary supplements and specializes in capsules, tablets,
liquids and semi-solids delivered in a variety of packaging
formats.
STRATEGIC IMPACT FOR RELEVIUM AND
BIOGANIX®
The registration of the NPN numbers allows
Bioganix® to enter the Canadian market with 400 Health Canada
approved products. Aurelio Useche, CEO of Relevium stated: “The
registration of 400 NPN products with Health Canada is an important
accomplishment for our company as it allows us to enter the
Canadian market with strength and it provides the Bioganix® brand
with a trusted status in terms of compliance”.
The manufacturing agreement with Bio V Pharma,
both a Health Canada and FDA registered and audited manufacturer,
provides the Company with relationships to major brick and mortar
retailers and gives us access to other international markets.
Richard Azani, CEO of Bio V Pharma stated: “We are very excited to
work with Relevium to develop the Canadian and US market for
Bioganix®. Our state-of-the-art facility in Montreal provides an
efficient, secure and compliant supply chain for our customers and
opens the door for the brand into retailers across the country, all
while ensuring the most stringent quality control standards in full
compliance with Health Canada and the FDA.”
The Company expects to enter the Canadian market
over the next few months with a selected line of products, expected
to be available for commercialization during the first quarter of
the new year.
About BioV Pharma Inc.Bio V
Pharma is a Quebec-based, full-service manufacturer of
pharmaceuticals and nutraceutical products including vitamins,
botanical products, and food supplements. With over 40 years of
experience in product development and manufacturing, Bio V Pharma
currently services North America, Europe and
the Middle East and is internationally recognized for
quality and service, while meeting the most stringent compliance
and documentation requirements. For more information please
visit www.biov.ca
About Relevium
TechnologiesRelevium is a publicly traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes
certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian and United States securities laws. All statements in this
news release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", or "would" occur. Forward-looking
statements are based on certain material assumptions and analysis
made by the Company and the opinions and estimates of management as
of the date of this press release. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release:Tel:
+1.888.528.8687RELEVIUM TECHNOLOGIES
INCEmail: investors@releviumcorp.comWebsite:
www.releviumtechnologies.comLike us on FacebookFollow us on
TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024